Vanda Pharmaceuticals
VNDA
160 hedge funds and large institutions have $1.2B invested in Vanda Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 57 increasing their positions, 40 reducing their positions, and 14 closing their positions.
188% more call options, than puts
Call options by funds: $4.21M | Put options by funds: $1.46M
179% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 14
43% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 40
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more capital invested
Capital invested by funds: $934M → $1.2B (+$264M)
19% more funds holding
Funds holding: 135 → 160 (+25)
5.6% more ownership
Funds ownership: 94.08% → 99.67% (+5.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$79.3M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$36.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.8M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$10.6M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$9.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$48.4M |
| 2 |
AC
Armistice Capital
New York
|
-$27M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$24.3M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.2M |
| 5 |
Morgan Stanley
New York
|
-$12.8M |
VNDA Hedge Fund Activity: Q3 2018 in Review
160 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2018, worth a combined $1.2B — up 28% from $934M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new VNDA positions and 14 closed out — a net gain of 25 holders — while 57 added to existing stakes and 40 trimmed.
The largest buyer was BlackRock, adding an estimated $79.3M. The largest seller was Avoro Capital Advisors, cutting an estimated $48.4M.
- 160 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2018, up from 135 in Q2 2018.
- Funds reported $1.2B of Vanda Pharmaceuticals stock for Q3 2018, up 28% quarter-over-quarter.
- 39 funds opened new Vanda Pharmaceuticals positions in Q3 2018 and 14 closed out, a net change of +25 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2018 was BlackRock, an estimated $79.3M added.
- The largest Vanda Pharmaceuticals seller in Q3 2018 was Avoro Capital Advisors, an estimated $48.4M sold.
Based on aggregated 13F filings for Q3 2018.